ALGN Stock Analysis — Align Technology
Sector: Medical Devices
AI Verdict
ALGN trades at 16.3x next year's earnings with nearly 100% EPS growth expected—this is cheap for the growth on offer if Invisalign's digital ecosystem keeps competitors at bay.
Competitive Moat
Align Technology dominates the clear aligner market with its Invisalign brand, protected by a large portfolio of patents and a proprietary digital treatment planning platform that locks in orthodontists and patients. Its digital workflow and data network create switching costs that smaller competitors struggle to match.
Summary
Align is notable for its Invisalign system, which leverages proprietary digital scanning and treatment planning to maintain customer lock-in.
Where It Stands
ALGN delivered a 1.99% one-year return, trades at 16.3x forward earnings (below the healthcare sector median of 22x), and has a neutral RSI of 59.6.
Key Metrics
- RSI: 59.6 — Neutral
- Trailing P/E: 32.7x
- Forward P/E: 16.3x
- PEG Ratio: 0.34
- Earnings Growth: +1.0%
- Revenue Growth: +0.0%
- Market Cap: $13.2B
- 1-Year Return: 1.99%
- 52-Week High: $208.31
- 52-Week Low: $122.00
Analyst Consensus
16 Buy · 6 Hold · 1 Sell (23 analysts)
Bull Case
Analysts expect 99.9% forward EPS growth, so the 16.3x forward P/E is cheap for the growth being projected.
Bear Case
If the P/E reverts back to the sector median of 22x without the forecasted EPS surge, upside is capped and the 1.99% one-year return shows the market is unconvinced so far.
Catalyst to Watch
Watch for quarterly earnings to confirm whether the near-doubling in EPS actually materializes, as this will determine if the low forward P/E is justified.